Navigation Links
Mindray Medical Completes Acquisition of Dragonbio's Orthopedics Business
Date:7/18/2012

SHENZHEN, China, July 18, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today the completion of its acquisition of Wuhan Dragonbio Surgical Implant's orthopedics business pursuant to the terms of the definitive agreement entered into on June 6, 2012.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that the forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, which was filed with the Securities and Exchange Commission on April 30, 2012. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

For investor and media inquiries, please contact:

In the U.S:
Hoki Luk
Western Bridge, LLC
Tel:   +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com

In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical to Present at AACC Clinical Lab Expo 2012
2. Mindray Announces First Quarter 2012 Financial Results
3. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
4. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
5. Concord Medicals Changan Hospital and Fox Chase Cancer Center Sign Strategic Alliance Agreement
6. Nonin Medical Named Platinum Partner by Tri-anim Health Services
7. Equinoxo2 Medical Announces Distribution of a New Portable Device
8. University of Ottawa Medical Research Arm Eliminates Storage Boundaries with EMC Isilon
9. The Biomedical Device Industry in America: Challenges at Home and Abroad
10. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
11. Merit Medical Systems Announces Earnings Release Date/Time And Conference Call Information For The Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up and ... and business owners should be aware that the summer months provide more than warmer ... locks and keys can be negatively affected from direct exposure to the sun. When ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... ... , ... By scoring 100% for fiscal management and accountability, the Arthritis National ... evaluator, Charity Navigator, validating ANRF's work as a top charity in America. , This ... and earns ANRF a spot on their “ 10 Charities Worth Watching ” list ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
Breaking Medicine News(10 mins):